Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia

Cancer

Volumn 117, Issue 14, 2011, Pages 3182-3186

  Ferrajoli, Alessandra ^a   Keating, Michael J ^a   O'Brien, Susan ^a   Cortes, Jorge ^a   Thomas, Deborah A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

chronic lymphocytic leukemia; early stage; rituximab; therapy

Indexed keywords

ALEMTUZUMAB; BETA 2 MICROGLOBULIN; CD19 ANTIGEN; CD5 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; PARACETAMOL; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; EARLY INTERVENTION; FEMALE; HUMAN; LEUKEMIA REMISSION; LONG TERM CARE; MALE; MONOTHERAPY; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED;

EID: 79959995569     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25853     Document Type: Article

References (18)

1. Horner MJ, Ries LAG, Krapcho M, et al. SEER cancer statistics review, 1975-2006. Bethesda, MD: National Cancer Institute. Available at:, posted to the SEER website, 2009.
2. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood. 1990; 75: 1414-1421.
3. Molica S,. Progression and survival studies in early chronic lymphocytic leukemia. Blood. 1991; 78: 895-899.
4. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 4990-4997. (Pubitemid 26189840)
5. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998; 338: 1506-1514.
6. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst. 1999; 91: 861-868.
7. Hallek M, Wanders L, Ostwald M, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma. 1996; 22: 439-447. (Pubitemid 26341010)
8. Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007; 109: 4679-4685. (Pubitemid 46827758)
9. Wierda WG, O'Brien S, Wang X, et al. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009; 27: 1637-1643.
10. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16: 2825-2833. (Pubitemid 28363048)
11. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1999; 10: 655-661. (Pubitemid 29342370)
12. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001; 19: 2153-2164. (Pubitemid 32366969)
13. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001; 19: 2165-2170. (Pubitemid 32366970)
14. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003; 21: 1746-1751. (Pubitemid 46638587)
15. Oscier D, Wade R, Orchard J, et al. Biological markers: data from the LRF CLL4 trial. Leuk Lymphoma. 2007; 48 (suppl 1): S4-S5.
16. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005; 23: 4079-4088. (Pubitemid 46211313)
17. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008; 112: 975-980.
18. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005; 23: 4070-4078. (Pubitemid 46211312)